Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...

Allogeneic hematopoietic stem cell transplantation leads to extensive skeletal homeostasis reconstruction and subsequent resolution of osteosclerosis in patients with myelofibrosis (MF), according to ...

Hematopoietic stem cell transplantation seems to be feasible and curative for some patients with myelofibrosis (MF) and splanchnic vein thrombosis leading to low early and overall mortality, according ...

The following is a summary of “Clearance of Driver Mutations after Transplantation for Myelofibrosis,” published in the January 2025 issue of Hematology by Gagelmann et al. Allogeneic hematopoietic ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a promising salvage treatment strategy for children with relapse-refractory LCH. However, many questions such as the efficacy and ...

"Myelofibrosis is harbored in 90% of ... which can be achieved only by hematopoietic stem cell transplantation. Here we could show that clearance of driver mutations on day 30 after allogeneic ...

We report clinical and electrophysiological improvement in a 49-year-old patient who underwent an autologous hematopoietic stem cell transplant (aHSCT) for thymoma-associated AIR after experiencing ...

They also achieved longer DFS and OS. Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation survived longer and exhibited reduce ...

A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem ... for patients receiving allogeneic stem cell transplantation, and 19% and 13% ...